Bruton’s Tyrosine Kinase Inhibitor

1 Drug classified under this drug class

Bruton’s Tyrosine Kinase Inhibitor. Ibrutinib 140 mg.
ORAL CAPS: 90, 120.
MCL: 560 mg (4× 140 mg caps.)×1/d.
CLL: 420 mg (3 ×140 mg caps.)×1/d.
Tmt. of adult pts. with (MCL) who have
received at least one prior ther.
This indication is based on overall
response rate.
An improv. in survival, dis.-related symp.
has not been established.
Tmt. of pts. with (CLL) who have received
at least one prior ther.
This indicat. is based on overall response
rate.
An improv. in survival, dis.-related symp.
has not been established.
C/I: None.